Annual zoledronic acid infusion lowers risk of fracture, death
No Thumbnail Available
Authors
Meeting name
Sponsors
Date
Journal Title
Format
Article
Subject
Abstract
Patients with a prior hip fracture have 2.5 times the risk of a new fracture compared to age-matched persons without a previous hip fracture. For patients with a recent hip fracture, intravenous zoledronic acid annually is an option for reducing the risk of new fractures and death. Stength of recommendation (SOR) B: based on one well- designed randomized controlled trial.
Table of Contents
DOI
PubMed ID
Degree
Thesis Department
Rights
OpenAccess.
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License.